Member Info for Fadec92

TSX Exchange (Canada) under PQE or OTC (US) under PQEFF

You can buy in HL fill or kill usually works if you cannot get a direct quote!

Aim tends too peak and pull back though, too hold gains needs a change of speed too bring forward more, something corporate, ie other companys have reversed into spac’s on Nasdaq and got £30m, or as said before an institution involved, i think they are quite happy plodding along while the moment passes by, would big money have instigated a faster pre-clinical or a faster phase trial into covid19... everyone will be vaccinated soon and the complications of severe ICU admissions will hopefully be gone, even the new variation of strains have been said too be protected by the vaccines so far, ok you could say this could be usefull in preparing the world of future SAR Covid variants but the current Covid was a freak of nature and unheard of so where would a future market come from, the Spanish flue went away and so will covid!

Its selling a product that holds the attention of bigger investment and returns that is the reality, look at Sierra perfect example that we all know of and taking Momelotinib into registration and a product that they have proved too the market with data that it will be better performing than current therapy and they have gained so many institutions, it’s because of money making!

The Galapogas is a Catalytic not Allosteric as it has the JAK if you are talking about GLPG3667

https://imgur.com/a/7b9xXGu

Thoth TTL Pharma TYK2/JAK1 i would have thought is a Catalytic kinase inhibitor with the JAK1 profile, the pseudokinase domain are the just TYK2 with v.high differentiations between all other JAK’s!

Potnak Parker could now be tweeting because he’s interested in raising the price, as it’s close too that time of year when they raise funds!

There’s the relationship in the Patent!

https://imgur.com/a/Fhlw1Eo

SDC-1801 is from the group of Compounds for the earlier FLT3/4 and Aurora, then at a later stage tested the molecules against the JAK/Tyk2 kinases selectivity and from that data their SDC was shown too have good TYK2 profiles, the FLT3 and Aurora are related from them compounds too, so the doubt is if they couldn’t get the formulation right for MTD in FLT3 and Aurora and having trouble with SDC-1801 it dose look similar and a risk imo!

Very good news this Bonanza Gold Hit!

“Miners want large deposits of higher-grade ore because it makes their operations more efficient. Higher-grade deposits yield more gold while requiring less work. Discovering a deposit of bonanza-grade gold is rare and bodes well for the future of a junior miner.”

https://www.streetwisereports.com/article/2019/08/05/recent-bonanza-grade-gold-intercepts-mean-these-companies-could-explode-higher-very-soon.html

The press releases of mining companies often contain industrial jargon that investors may not understand. One example is the term "bonanza-grade gold."

Grade refers to the extent of mineralization of a deposit of metal ore. The higher the grade, the more gold there is inside a smaller space of rock.

Sorry Stoney didn’t read your post I think the same as you, some wild stuff about tweaking of formula being discussed so passed by a lot of it!

Its the updated Patent for SDC-1801 in the US always wondered and been saying since the last Patent Grant In November 2020, as could not find anything on it!

https://imgur.com/a/Iquc5O8

Probably been shared before but a good addition on the subject!

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high- grade ovarian cancer

https://jhoonline.biomedcentral.com/track/pdf/10.1186/s13045-020-00874-6.pdf

Role of gemcitabine in ovarian cancer treatment

Conclusions

In conclusion, literature data provide sufficient information to support the efficacy and the safety of Gemcitabine in ovarian cancer treatment. Gemcitabine has been shown to have a significant activity with an acceptable toxicity profile in previously treated ovarian cancer patients as a single agent or in combination with other drugs.

https://www.annalsofoncology.org/article/S0923-7534(19)38216-X/pdf

Sadoldgit LDG (Low Dose Gemcitabine) combo could potentially reduce this further hopefully!

There’s not much too see in there anyhow I don’t think the research has been uploaded, have too create an account, got info from this tweet!

https://twitter.com/lauramezquitamd/status/1381151494645354497?s=21

Here’s a relevant posted at the AACR with NSCLC she is saying that germline variants is 77% in DNA repair pathways in this study, can’t find the full research yet don’t know it’s up yet!

https://cattendee.abstractsonline.com/meeting/9325/Presentation/1392

I’m sure what Krone was saying probably fits the bill, saying that Dilly said they had a nice Chk1 in their back pocket, Not the front pocket!

When they are ready too do something with it they will, and will be able too see that from a trial application Krone would usually find something and this site is always ahead of itself with this or that is happening, haven’t seen a clear sign yet but the 6-7% fund is a sign maybe, but something more conclusive would be better!

Thanks Potnak what underpins the assumption that SRA737 is now being developed, is there an application from Sierra?

Morning, why is there an expectation of news from Sierra after April, is this based on the ICR poster at the AACR meeting?

Ha ha!